Close Menu

NEW YORK — RNA Disease Diagnostics said on Thursday that it has acquired an exclusive worldwide license to a diagnostic technology — owned by the University of Maryland, Baltimore and the University of Maryland, Baltimore County — that it will use to develop a rapid, point-of-care for SARS-CoV-2.

According to the company, the technology uses antisense oligonucleotides to detect infectious disease gene sequences and can provide results within 45 minutes. It will initially use the technology to develop a point-of-care test for SARS-CoV-2, followed by a home-use test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Apr
29
Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May
13
Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

May
18
Sponsored by
Bio-Rad

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.